

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *					2. Issuer Name and Ticker or Trading Symbol								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
PETERS WILLIAM J						Amphastar Pharmaceuticals, Inc. [ AMPH]							Director 10% Owner				
(Last) (First) (Middle)				3.	3. Date of Earliest Transaction (MM/DD/YYYY)								_X_ Officer (give title below) Other (specify below) CFO, EVP & Treasurer				
C/O AMPHA PHARMACI	EUTICA	LS, INC	C., 1157	0			5/19	9/20	)22								
6TH STREE RANCHO C	(Stree	NGA, C			If An	nendmei	nt, Date O	rigin	al File	d (MM/DI	D/YYY	X Form filed b	y One Repor			icable Line)	
(C	ny) (Stat			- Non-Dei	rivati	ve Secu	ırities Acq	uire	ed, Dis	posed o	f, or l	Beneficially Owne	ed				
1. Title of Security (Instr. 3)				Trans. Date	Exec	Deemed ution if any	3. Trans. Co. (Instr. 8)	de	4. Securities Acquire or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securi Following Reported (Instr. 3 and 4)	ties Beneficially Owned Transaction(s)		Ownership Form: Be Direct (D) Ov	Beneficial Ownership	
							Code	V	Amour	(A) or (D)	Price	•			or Indirect (I) (Instr. 4)	(Instr. 4)	
Common Stock				5/19/2022			F		378 (1	D	\$33.7	0	104609		D		
	Tabl	e II - Der	ivative S	Securities	Bene	ficially	Owned (	e.g.,	puts,	calls, wa	rrant	s, options, conve	tible secu	rities)			
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deem Execution Date, if an	(Instr. 8)	s. Code 5. Numb B) Derivativ Acquirec Disposec (Instr. 3,		ve Securities I (A) or I of (D)		6. Date Exercisable and Expiration Date			e and Amount of ties Underlying tive Security 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	Ownership Form of	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exer	e rcisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)			

#### **Explanation of Responses:**

(1) The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units, or RSUs.

### **Reporting Owners**

Panarting Owner Name / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
PETERS WILLIAM J C/O AMPHASTAR PHARMACEUTICALS, INC. 11570 6TH STREET RANCHO CUCAMONGA, CA 91730			CFO, EVP & Treasurer				

#### **Signatures**

/s/ William J. Peters 5/20/2022

\*\*Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.